HOTEL INFO: please call us to assist with your reservation

Westin Anaheim Resort $339 per night, single or double occupancy.

https://www.marriott.com/en-us/hotels/snawa-the-westin-anaheim-resort

Dr. Sandra Benavides Caballero, PharmD, FCCP, FPPA

Dr. Sandra Benavides is the Associate Director of Outcomes and Assessment at KnowFully Learning Group. A distinguished pediatric pharmacy specialist and educator, Dr. Benavides has dedicated her career to advancing pediatric pharmacotherapy and pharmacy education. Her extensive scholarship includes numerous peer-reviewed articles and edited textbooks that serve as cornerstones for pediatric medication management. A Fellow of both ACCP and PPA, she is a frequent national speaker recognized for translating complex clinical data into actionable practice pearls for pharmacists.

Friday March 12, 2027

THE EVOLVING LANDSCAPE OF PEDIATRIC CARE: CLINICAL CONTROVERSIES & EQUITABLE SOLUTIONS

ACPE# TBA

Objectives:

1.  Evaluate the safety and efficacy of OTC cough, cold, and allergy products in the pediatric population, focusing on age-restricted ingredients and FDA-safety communications.

2.  Formulate a symptom-based treatment plan for the pediatric common cold, prioritizing non-pharmacologic interventions and evidence-based supportive care.

3.  Appraise pharmacologic strategies for common pediatric behavioral disorders, including monitoring for adverse drug events and long-term growth suppression.

4.  Critique the evidence and proposed theories regarding dietary supplements and restrictive diets used in the management of pediatric behavioral disorders.

5.  Assess the role of GLP-1 agonists and traditional pharmacotherapy in pediatric obesity, including clinical benefits and long-term limitations.

6.  Analyze the impact of social determinants of health (SDOH) on pediatric outcomes and identify pharmacist-led interventions to bridge gaps in health equity, such as addressing medication affordability and health literacy.

Saturday March 13, 2027

CLEARING THE AIR: PHARMACOTHERAPY AND PREVENTION IN PEDIATRIC RESPIRATORY DISEASE

ACPE# TBA

Objectives:

1.  Analyze the epidemiology of common pediatric respiratory infectious diseases to identify seasonal trends and high-risk patient populations.

2.  Evaluate clinical presentation and biomarkers to differentiate between viral and bacterial respiratory infections in pediatric patients.

3.  Optimize a pharmacotherapeutic treatment plan for pediatric respiratory infections, incorporating weight-based dosing and evidence-based guideline updates.

4.  Design pharmacist-led prevention strategies, including immunization advocacy and caregiver education, to reduce the incidence of pediatric respiratory disease.

5.  Assess the risk of drug-related complications and morbidity in pediatric patients to improve safety and long-term clinical outcomes.

Sunday March 14, 2027

SMALL LUNGS, MODERN MEDS: MASTERING PEDIATRIC ASTHMA MANAGEMENT & BIOLOGIC UPDATES

ACPE# TBA

Objectives:

1.  Identify clinical and environmental risk factors that contribute to pediatric asthma exacerbations, including SABA overuse as a key safety marker.

2.  Evaluate the mechanism of action and clinical utility of FDA-approved biologics (e.g., Omalizumab, Dupilumab) for moderate-to-severe pediatric asthma.

3.  Differentiate between GINA and NAEPP updates, specifically regarding the transition to SMART (Single Maintenance and Reliever Therapy) in children aged 5-11.

4.  Design a pediatric-specific pharmacotherapy plan that optimizes inhaled corticosteroid (ICS) dosing and delivery devices (spacers, VHCs) for long-term control.

5.  Develop a patient-centered counseling framework to address inhaler technique, adherence barriers, and the importance of an Asthma Action Plan.